医学
抗精神病药
精神分裂症(面向对象编程)
精神科
血清素转运体
双相情感障碍
奥氮平
多巴胺受体D2
药品
萧条(经济学)
药理学
多巴胺
锂(药物)
血清素
内科学
受体
经济
宏观经济学
作者
Martin Tarzian,Mariana Ndrio,Byron Chique,Japjit Serai,Bryce Thalackal,Joseph T. F. Lau,Adegbenro Omotuyi John Fakoya
出处
期刊:Cureus
[Cureus, Inc.]
日期:2023-09-28
摘要
This drug review provides a comprehensive analysis of a novel antipsychotic called lumateperone, marketed as Caplyta. Lumateperone gained FDA approval in 2019 for treating schizophrenia and later, in 2021, for treating bipolar depression. The review begins by delving into lumateperone's mechanism of action, which involves the partial agonism of the dopamine D2 receptor as well as its unique effects on the dopamine transporter, N-methyl-D-aspartate (NMDA) receptor, and serotonin transporter. Additionally, the study examines lumateperone's distinctive pharmacokinetics. Moreover, this review assesses lumateperone's metabolic profile and highlights its favorable outcomes regarding mean body weight, BMI, and waist circumference, surpassing those of other second-generation antipsychotic medications. The study explicitly emphasizes the efficacy and safety of lumateperone in treating schizophrenia and bipolar depression associated with bipolar I and II disorders. An extensive investigation of multiple clinical trials provides compelling evidence of lumateperone's advantages over existing antipsychotic medications. The review also acknowledges the limitations of lumateperone compared to other antipsychotics. In conclusion, this drug review underscores the importance of further research to uncover the additional limitations of lumateperone while acknowledging its promising benefits and potential for advancing treatment options.
科研通智能强力驱动
Strongly Powered by AbleSci AI